1. Home
  2. IBP vs NUVL Comparison

IBP vs NUVL Comparison

Compare IBP & NUVL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Installed Building Products Inc.

IBP

Installed Building Products Inc.

HOLD

Current Price

$286.27

Market Cap

8.3B

ML Signal

HOLD

Logo Nuvalent Inc.

NUVL

Nuvalent Inc.

HOLD

Current Price

$98.89

Market Cap

8.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
IBP
NUVL
Founded
1977
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Homebuilding
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
8.3B
8.1B
IPO Year
2014
2021

Fundamental Metrics

Financial Performance
Metric
IBP
NUVL
Price
$286.27
$98.89
Analyst Decision
Hold
Strong Buy
Analyst Count
8
15
Target Price
$276.00
$135.33
AVG Volume (30 Days)
323.4K
437.9K
Earning Date
01-01-0001
05-27-2026
Dividend Yield
1.17%
N/A
EPS Growth
6.70
N/A
EPS
9.71
N/A
Revenue
$2,970,800,000.00
N/A
Revenue This Year
$2.46
N/A
Revenue Next Year
$4.53
$1,064.25
P/E Ratio
$29.66
N/A
Revenue Growth
1.00
N/A
52 Week Low
$150.83
$55.54
52 Week High
$349.00
$113.02

Technical Indicators

Market Signals
Indicator
IBP
NUVL
Relative Strength Index (RSI) 40.56 44.15
Support Level $254.83 $98.37
Resistance Level $293.53 $107.13
Average True Range (ATR) 13.62 3.66
MACD -4.44 -0.27
Stochastic Oscillator 24.63 29.17

Price Performance

Historical Comparison
IBP
NUVL

About IBP Installed Building Products Inc.

Installed Building Products Inc is an insulation installer serving the residential new construction market and are also a diversified installer of complementary building products, including waterproofing, fire-stopping and fireproofing, garage doors, rain gutters, window blinds, shower doors, closet shelving, mirrors and other products throughout the United States. The company installs fiberglass insulation, spray foam insulation, and cellulose insulation. The company has three operating segments consisting of Installation, Manufacturing and Distribution operations. Majority of revenue is derived from Installation segment.

About NUVL Nuvalent Inc.

Nuvalent Inc is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of its operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically validated kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.

Share on Social Networks: